基于人工智能的区域处方前置审核的实践与成效

Practice and Effect of Pre-review of Regional Prescriptions Based on Artificial Intelligence

关键词:  区域  处方前置审核系统  合理用药  同质化

Key words:  regional  pre-prescription review system  reasonable medication  homogenization

摘要:

目的 探讨区域处方前置审核系统对提高区域内13家医院门诊合理用药水平的影响。方法 通过区域处方前置审核系统，收集2019年1-12月区域13家医院门诊处方，回顾性分析处方的审核率、干预率、拦截率、合格率以及平均处方费用变化。结果 2019年1-12月共审核区域门诊处方416万余张，总干预率达4.38%，总拦截率达0.64%，审核率达100%。第四季度与第一季度相比，干预率从6.82%下降至2.62%，拦截率从1.08%下降至0.39%，区域门诊处方合格率从93.19%提升至97.85%，区域平均处方药品费用从（103.31±40.25）元下降至（75.87±31.18）元。结论 通过区域处方前置审核系统，从事前、事中、事后3个维度全方位实现处方规范化、协同化、同质化用药管理，从而提高患者的用药安全，促进合理用药，降低患者的药品费用，改善药学服务质量。

Abstract:

OBJECTIVE To explore the influence of the regional pre-prescription review system on improving the level of rational medication in outpatient clinics of 13 medical institutions in the region. METHODS Outpatient prescriptions of 13 medical institutions in the region from January to December 2019 was collected by the pre-review system of regional prescriptions. And retrospectively analyzed the prescription review rate, intervention rate, interception rate, pass rate and average prescription cost changes. RESULTS From January to December 2019, more than 4.16 million regional outpatient prescriptions were reviewed, with a total intervention rate of 4.38%, a total interception rate of 0.64%, and a review rate of 100%. Compared the fourth quarter with the first quarter, the intervention rate decreased from 6.82% to 2.62%, the interception rate decreased from 1.08% to 0.39%, the regional outpatient prescription pass rate increased from 93.19% to 97.85%, and the regional average prescription drug cost from (103.31±40.25)yuan fell to (75.87±31.18)yuan. CONCLUSION Through the regional pre-prescription review system, the three dimensions of pre-event, mid-event and post-event are engaged to realize the standardized, coordinated, and homogenized drug management of prescriptions, thereby improving the safety of patients' medications, promoting rational medications and reducing patients' medications cost, to finally improve the quality of pharmaceutical services.